Document is current
Any future updates will be listed below
-
Authors
Szebeni, Janos
Simberg, Dmitri
González-Fernández, África
Barenholz, Yechezkel
Dobrovolskaia, Marina A.
- License Information
-
More Information
Article History
Received: 16 April 2018
Accepted: 3 September 2018
First Online: 22 October 2018
Competing interests
: J.S. is involved in SeroScience Ltd’s CRO activity providing immune toxicology services. J.S. and Y.B. are co-inventors on US patent 9,078,812B2, 14 July 2015, relevant to the use of liposomal carrier as desensitizing agent and co-owned by Semmelweis University, Hungary and Hebrew University, Israel. Y.B. is one of the inventors of two patents relevant to Doxil: US Patent 5,192,549, 9 March 1993, and US Patent 5,316,771, 31 May 1994. Both patents expired in March 2010. The Hebrew University received royalties from Doxil sales until the patent expiration. The Barenholz Fund, established with a portion of these royalties, is used to support research in Y.B.’s laboratory, including this study. The other authors declare no competing interests related to the subject described in the manuscript.
